NDAINTRAVENOUSPOWDER
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
[see Clinical Pharmacology ()].
Pharmacologic Class:
Lipopeptide Antibacterial
Indications (15)
pneumonialeft-sided infective endocarditis due to Sskin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates)Streptococcus pyogenesStreptococcus agalactiaeStreptococcus dysgalactiae subspincluding adult patients with right-sided infective endocarditiscaused by methicillin-susceptiblemethicillin-resistant isolatesdevelopment of drug-resistant bacteriamaintain the effectiveness of Daptomycin for Injectionother antibacterial drugsDaptomycin for Injection should be used only to treatprevent infectionsstrongly suspected to be caused by susceptible bacteria
Clinical Trials (5)
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
Started Dec 2018
18 enrolled
BacteremiaSoft Tissue InfectionsSkin Diseases, Infectious
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
Started May 2014
12 enrolled
Drug InteractionsPharmacokinetics
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
Started Sep 2013
149 enrolled
Acute Hematogenous Osteomyelitis
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
Started Nov 2012
Bacteremia
Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
Started May 2012
10 enrolled
Nosocomial InfectionHealthcare-associated Infection